SCHEDULE: Vanguard Discloses 4.49% Stake in Rani Therapeutics

Vanguard Capital Management has reported a beneficial ownership of 4.49% in Rani Therapeutics Holdings Inc. as of June 30, 2026.

Summary

• Vanguard Capital Management, through its affiliates and managed accounts, now beneficially owns 5,052,862 shares of Rani Therapeutics Holdings Inc. common stock.
• This represents a 4.49% ownership stake in the company as of the reporting date.
• Vanguard has sole voting power over 489,877 shares and sole dispositive power over 5,052,862 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it indicates increased institutional interest from a major player, but it's a passive stake without direct operational involvement.

Positives

• Significant institutional ownership by a major asset manager like Vanguard can provide stability and confidence to the market.
• Vanguard's investment indicates a belief in Rani Therapeutics' long-term prospects, potentially attracting further investment.

Negatives

• The filing does not contain any negative financial or operational information about Rani Therapeutics itself, as it is a Schedule 13G disclosure of ownership.

Risks

• As a Schedule 13G filing, it indicates passive investment, meaning Vanguard is not seeking to control or influence the company's management or operations. This implies no direct strategic support or intervention from Vanguard.
• The 4.49% stake, while significant, does not grant Vanguard controlling interest, leaving the company's strategic direction dependent on its current management and board.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Rani Therapeutics Holdings Inc.

Industry Context

StockSavvy.ai notes that significant institutional filings like this from major asset managers such as Vanguard often signal a level of confidence in the underlying company's sector or specific business model, even if the investment is passive.

Comparison to Industry Standards

• A 4.49% stake by a single institutional investor is a common threshold for significant passive ownership in publicly traded companies.
• Many institutional investors, including Vanguard, manage portfolios that include companies in the biotechnology and therapeutics sector, aligning with Rani Therapeutics' industry.

Stakeholder Impact

• Shareholders may view Vanguard's increased stake as a positive signal, potentially leading to increased investor confidence.
• The company's management and board will operate with the awareness of significant passive institutional ownership.

Next Steps

• Monitor future filings from Vanguard and Rani Therapeutics for any changes in ownership or company strategy.
• Observe market reaction to this disclosure, which may influence investor sentiment.

Key Dates

Keywords

Rani Therapeutics, Vanguard, Institutional Ownership, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management